MYGN
Myriad Genetics, Inc.
MYGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
MYGN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Under pressure |
MYGN's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
MYGN PE Valuation
MYGN has no meaningful PE right now: it lost money over the past year.
MYGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect MYGN's losses to grow, with revenue declining. However, they disagree widely on these estimates.
MYGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.37 | +$2.96 |
| Q2 2026 | -$1.20 | +$3.08 |
| Q1 2026 | -$4.31 | -$3.19 |
| Q4 2025 | -$3.95 | -$2.54 |
| Q3 2025 | -$4.33 | -$3.05 |
| Q2 2025 | -$4.28 | -$2.49 |
| Q1 2025 | -$1.12 | +$1.68 |
| Q4 2024 | -$1.41 | +$1.77 |
MYGN is still losing money, but far less than before: $1.37 per share over the past year, against $4.33 at its worst in late 2025.
MYGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $202.7M | -1.5% |
| Q2 2026 | $190.7M | -11% |
| Q1 2026 | $200.4M | +2.3% |
| Q4 2025 | $209.8M | -0.4% |
| Q3 2025 | $205.7M | -3.6% |
| Q2 2025 | $213.1M | +0.8% |
| Q1 2025 | $195.9M | -3.1% |
| Q4 2024 | $210.6M | +7.1% |
MYGN's revenue grew through 2023 and has held roughly level since: $203M last quarter, down 1.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -8.3 points |
| Q2 2026 | -20% | +134 points |
| Q1 2026 | -15% | -0.5 points |
| Q4 2025 | -2.7% | +16 points |
| Q3 2025 | -11% | -1.9 points |
| Q2 2025 | -154% | -137 points |
| Q1 2025 | -15% | -1 points |
| Q4 2024 | -19% | -2.5 points |
MYGN's operating margin was −20% last quarter, down 8.3 points from the same quarter a year ago.
MYGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5M | -131% |
| Q2 2026 | -$8.3M | +$5.3M |
| Q1 2026 | -$15.7M | +$600K |
| Q4 2025 | $10.6M | +61% |
| Q3 2025 | $21.1M | +2914% |
| Q2 2025 | -$13.6M | -623% |
| Q1 2025 | -$16.3M | +$2.3M |
| Q4 2024 | $6.6M | +$61.3M |
MYGN has burned cash in most quarters: −$20M over the past year, against −$2M the year before.
MYGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +900K shares |
| 1 year | +2.8% | +2.6M shares |
| 3 years | +17% | +13.8M shares |
| 5 years | +17% | +14.2M shares |
| Available history | +29% | +21.3M shares |
MYGN has 96M diluted shares, up 2.8% from a year ago.
MYGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | 3.3x | Elevated |
MYGN's net debt is about 3.3 years of its operating earnings (EBITDA).
MYGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 80.3 | Overbought |
MYGN's weekly RSI is 57 (neutral) and its Stochastic is 80 (overbought).
MYGN PE vs Healthcare Sector
MYGN has no meaningful PE right now: it lost money over the past year.
MYGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.10 | 11% above |
| 20 week MA | $4.52 | 26% above |
| 50 week MA | $4.88 | 16% above |
| 100 week MA | $6.48 | 12% below |
| 200 week MA | $13.8 | 59% below |
MYGN has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 59% below its 200-week average.
MYGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.8 | $18.4 | -31% |
| 2021 | $18.4 | $27.3 | +48% |
| 2022 | $27.3 | $15.6 | -43% |
| 2023 | $15.6 | $19.1 | +22% |
| 2024 | $19.1 | $13.4 | -30% |
| 2025 | $13.4 | $6.48 | -52% |
| 2026 YTD | $6.48 | $5.68 | -12% |
MYGN has finished lower in four of the last six years. It's down 12% so far in 2026.